Seclidemstat mesylate

N/A

Report date: 2026/04/13 20:02:18
NME

Base Information

Drug NameSeclidemstat mesylate
Drug Alias NameSeclidemstat - Salarius PharmaceuticalsseclidemstatHCI-2577SP-2577 (free base)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLysine-specific histone demethylase 1 inhibitors
TargetsLysine-specific histone demethylase 1
Therapy Area/IndicationsSolid tumoursChondrosarcoma, Extraskeletal MyxoidMyelodysplastic Syndromes +[17] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSalarius Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesSalarius PharmaceuticalsSalarius Pharmaceuticals LlcThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesHonorhealth Research Institute
Active IndicationsChondrosarcoma, Extraskeletal MyxoidMyelodysplastic SyndromesDesmoplastic Small Round Cell Tumor +[12] 
Inactive IndicationsSolid tumoursEndometrial NeoplasmsOvarian Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A